Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 25:17:11795549231187264.
doi: 10.1177/11795549231187264. eCollection 2023.

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Eduardo Gonzalez-Ochoa  1 , Ana C Veneziani  1 , Amit M Oza  1   2
Affiliations
Review

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Eduardo Gonzalez-Ochoa et al. Clin Med Insights Oncol. .

Abstract

Ovarian cancer is the second leading cause of death from gynecologic malignancies worldwide. Management of platinum-resistant disease is challenging and clinical outcomes with standard chemotherapy are poor. Over the past decades, significant efforts have been made to understand drug resistance and develop strategies to overcome treatment failure. Antibody drug conjugates (ADCs) are a rapidly growing class of oncologic therapeutics, which combine the ability to target tumor-specific antigens with the cytotoxic effects of chemotherapy. Mirvetuximab soravtansine is an ADC comprising an IgG1 monoclonal antibody against the folate receptor alpha (FRα) conjugated to the cytotoxic maytansinoid effector molecule DM4 that has shown promising clinical activity in patients with FR-α-positive ovarian cancer. This review summarizes current evidence of mirvetuximab soravtansine in platinum-resistant ovarian cancer, focusing on clinical activity, toxicity, and future directions.

Keywords: Antibody drug conjugate; folate receptor; mirvetuximab; ovarian cancer; platinum resistance.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: EG reports no conflict of interest. AV reports no conflict of interest; AO reports no conflict of interest; PI and Steering Committees with AstraZeneca, GSK, and Clovis. Advisory Boards AstraZeneca and Morphosys.

Figures

Figure 1.
Figure 1.
Mirvetuximab soravtansine mechanism of action.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. - PubMed
    1. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237-249. - PubMed
    1. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615. - PMC - PubMed
    1. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. - PMC - PubMed
    1. Stuart GC, Kitchener H, Bacon M, et al.. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750-755. - PubMed

LinkOut - more resources